Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
Effect of Diet and Electrical Stimulation Exercise on Blood Pressure Control in Spinal Cord Injury
Official Title Lifestyle solutions to postprandial hypotension in spinal cord injuryPurpose
To test if a low-glycemic diet and electrical stimulation of leg muscles can improve blood pressure control after eating.
Could this study be right for you?
- Spinal cord injury sustained at least 1-year ago
- Level of injury between C4 and T10
- Use of wheelchair for majority of daily activities
Age Range
18 years and up -
Making Colorectal Cancer Screening Simple and Accessible Through Technology
Official Title Digital Transformation of CRC Screening: Revolutionizing Access and Saving LivesPurpose
The purpose of this study is to conduct usability testing to evaluate ease of use and overall user experience of a website designed to promote colorectal (CRC) awareness and screening uptake among adults 45-64.
Could this study be right for you?
Inclusion Criteria: Eligible participants will 1) be between the ages of 45-64, 2) at average risk for CRC and 3) from diverse racial/ethnic and socioeconomic backgrounds
Those who are ineligible fall under the following categories:
-
Age: Individuals outside the age range of 45-64 will be excluded
-
Pregnancy Status: Pregnant individuals will be excluded from the study. since CRC screening is not recommended for pregnant individuals
Age Range
45 - 64 years -
-
Does the amount of nicotine in filtered little cigars impact health and smoking habits?
Official Title LOWFLC Study: Addiction potential of low nicotine filtered little cigarsPurpose
Researchers from The Ohio State University are recruiting adult users of little cigars and cigarillos to help improve understanding of the products’ health impact.
Could this study be right for you?
- Current smoker
- No significant health problems
Age Range
21 - 75 years -
A Study for Reducing Alcohol Use During MOUD (Phase Two)
Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)Purpose
This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.
The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.
Could this study be right for you?
Inclusion Criteria:
- engaged in MOUD treatment (for at least one month)
- alcohol consumption (within the past 12 months)
- age 18 or older
- access to a smart phone
(partial list of inclusion criteria)
Exclusion Criteria:
- diagnosis of psychosis or bipolar I
- currently pregnant (positive pregnancy test)
(partial list of exclusion criteria)
Age Range
18 years and up -
A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression
Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive DisorderPurpose
Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.
The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.
Could this study be right for you?
You may be able to take part if you:
• are 18–65 years of age
• have a confirmed diagnosis of Major Depressive Disorder (MDD)
• feel that your current antidepressant medication is not working well
• Has tried 2 or more antidepressant medication in the current episode of depression
Other criteria will need to be met to confirm your eligibility for this study.
Age Range
18 - 65 years -
A First-in-human Study of a New Gene Therapy (AMT-260) in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)Purpose
You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).
The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.
AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.
The overall goals of this study are:
- To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
- To measure if participants have changes in:
- frequency of their seizures
- how their seizures affect their life
- how the human body takes up and removes AMT-260
- To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.
Could this study be right for you?
Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.
Age Range
18 - 65 years -
Teen Depression Study
Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)Purpose
We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.
A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.
Could this study be right for you?
Inclusion Criteria:
- 14-18 years of age at enrollment
- Youth assent and parent consent
Exclusion Criteria:
- Metal braces, tattoos with metal
- Claustrophobia
- Current pregnancy
Age Range
14 - 18 years -
A Study to Evaluate Lutikizumab in Adults with Moderate to Severe Hidradenitis Suppurativa
Official Title A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis SuppurativaPurpose
The purpose of this study is to evaluate the efficacy of lutikizumab
Could this study be right for you?
- Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
- Subject must have tried a 12-week (about 3 months) trial of oral antibiotics with inadequate improvement
- Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
- Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
Age Range
18 years and up -
A Study to Evaluate Minoxidil for Treatment of Hair Loss in Patients with Breast Cancer on Endocrine Therapy
Official Title A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer PatientsPurpose
The purpose of this study is to evaluate the efficacy of minoxidil.
Could this study be right for you?
- Subjects must have a diagnosis of breast cancer stages I-IV
- Subjects must have hair loss while on endocrine therapy (i.e., tamoxifen or an aromatase inhibitor such as anastrozole)
- Subjects must not be on chemotherapy or have been on chemotherapy within 2 years
- Subjects must not have tried oral or topical minoxidil or spironolactone previously
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
Age Range
18 - 70 years -
A Study to Evaluate Anifrolumab in Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus
Official Title A Multicenter Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial TherapyPurpose
-
Subject must have a diagnosis of cutaneous lupus erythematosus
-
Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects
-
Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C
-
Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
Could this study be right for you?
- Subject must have a diagnosis of cutaneous lupus erythematosus
- Subject must have tried antimalarial treatment (i.e., hydroxychloroquine, quinacrine, or chloroquine) for at least 12 weeks (about 3 months) or was unable to tolerate antimalarial treatment due to side effects
- Subject must be in good general health with no history of tuberculosis, cancer, HIV, or hepatitis B or C
- Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study
Age Range
18 - 70 years -
-
Social Abilities and Aging Study
Official Title Progression of Social Cognitive Deficits in Mid- and Late-Life Schizophrenia Spectrum DisordersPurpose
This research is being done to investigate the effects of age on social cognition in schizophrenia spectrum disorder. The study also hopes to examine potential neural bases of social cognition. The findings of the research will help develop effective treatment strategies by identifying who, when, and how to intervene.
Could this study be right for you?
Patients:
- Diagnosis of a schizophrenia spectrum disorder (includes schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, schizophreniform disorder, unspecified or other-specified psychotic disorders)
Healthy Controls:
- No history of any psychotic disorder
- No psychiatric diagnosis in the last 5 years
- Not taking psychotropic medication
Age Range
35 - 75 years -
An Investigational New Drug for the Treatment of Alzheimer’s Disease
Official Title A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Escalating Doses of LH-001 in Healthy SubjectsPurpose
The purpose of this study is to evaluate the safety and tolerability of an investigational new drug in healthy participants aged 18-60 years.
Could this study be right for you?
- In good health and BMI (ratio of body weight to height) between 18-29.9 kg/m2
- Willing to participate in various research assessments including blood collection, urine collection, electrocardiogram, and vital signs
- Willing to stay overnight (~30 hours) in the OSU Hospital Clinical Research Center
- If sexually active, willing to utilize highly effective birth control during the study period
- Not currently pregnant or breast-feeding
- No significant medical condition involving any major organs (heart, lung, liver, brain, or endocrine)
- No to any of the following: alcohol or substance abuse, spleen problems, or drug hypersensitivity
- No history of or undergoing treatment for: major psychiatric illness, seizures, or autoimmune disease
- Not currently taking immunosuppressive drugs
- No active Hepatitis B, Hepatitis C, or HIV
- No cancer history within 5 years (squamous and basal cell skin cancer excluded)
Age Range
18 - 60 years